TONY LEUANG: Open Payments
NPI 1265812374 · INDIO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,053 in 156 payments from 19 companies in 2025. Trend: 2023 $2,547 · 2024 $3,232 · 2025 $3,053
Food & beverage: $2,973Education: $80
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 11 | $415 |
| LEO Pharma Inc. | 20 | $401 |
| ABBVIE INC. | 19 | $341 |
| Lilly USA, LLC | 14 | $262 |
| Amgen Inc. | 17 | $262 |
| Arcutis Biotherapeutics, Inc. | 17 | $235 |
| Galderma Laboratories, L.P. | 16 | $234 |
| UCB, Inc. | 9 | $202 |
| Regeneron Healthcare Solutions, Inc. | 10 | $172 |
| Novartis Pharmaceuticals Corporation | 6 | $133 |
Products named: DUPIXENT, ADBRY, TALTZ, OTEZLA, SKYRIZI, Zoryve, NEMLUVIO, Bimzelx.
Industry payments across CA — which companies pay providers there.
